Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-899927b87eee0edddf78e53b80fec139",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-899927b87eee0edddf78e53b80fec139",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-899927b87eee0edddf78e53b80fec139",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-899927b87eee0edddf78e53b80fec139\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-899927b87eee0edddf78e53b80fec139</b></p><a name=\"composition-en-899927b87eee0edddf78e53b80fec139\"> </a><a name=\"hccomposition-en-899927b87eee0edddf78e53b80fec139\"> </a><a name=\"composition-en-899927b87eee0edddf78e53b80fec139-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1660/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - zokinvy</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/22/1660/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp899927b87eee0edddf78e53b80fec139"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - zokinvy",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Zokinvy is and what it is used for</li><li>What you need to know before you take Zokinvy</li><li>How to take Zokinvy</li><li>Possible side effects</li><li>How to store Zokinvy</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What zokinvy is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What zokinvy is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Zokinvy is</p><p>Zokinvy contains the active substance lonafarnib.</p><p>What Zokinvy is used for</p><p>This medicine is used to treat patients aged 12 months and older with the following rare disorders:</p><ul><li>Hutchinson-Gilford progeria syndrome</li><li>processing-deficient progeroid laminopathies</li></ul><p>These illnesses are caused by changes in genes needed to make certain proteins. Normal versions of these proteins help to keep cells strong and stable. However, the altered genes cause a build-up of harmful forms of the proteins called progerin or progerin-like proteins. These harmful proteins lead to cell damage that resembles the effects of aging.</p><p>How Zokinvy works</p><p>Zokinvy works by helping to reduce the build-up of the harmful progerin or progerin-like proteins.</p></div>"
}
},
{
"title" : "2. What you need to know before you take zokinvy",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take zokinvy"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Zokinvy</p><ul><li><p>if you are allergic to lonafarnib or any of the other ingredients in this medicine (listed in section 6).</p></li><li><p>with medicines known as strong CYP3A inhibitors (these can reduce the breakdown of Zokinvy in the body, leading to more side effects, see Other medicines and Zokinvy, below).</p></li><li><p>with the medicine midazolam</p></li><li><p>with the medicines atorvastatin, lovastatin, simvastatin</p></li><li><p>if you have severe hepatic (liver) impairment</p></li></ul><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before taking Zokinvy.</p><p>Please tell your doctor immediately if you:</p><ul><li>are over 10 years of age. Treatment results can vary depending on the age when you start taking Zokinvy.</li><li>have persistent vomiting or diarrhoea and prolonged loss of appetite or weight (see section 4).</li><li>start to take the anti-diarrhoeal medicine loperamide. Because of the interaction between Zokinvy and loperamide, it will be important for your doctor to provide dosing guidance and monitor your use of this medicine.</li><li>are having surgery. You must not use midazolam, a medicine commonly used during surgery, with Zokinvy. Your doctor can provide instructions for this situation.</li><li>experience increased levels of liver enzymes shown by blood tests. Your doctor should monitor your liver function while taking this medicine.</li><li>develop any symptoms of kidney problems. Your doctor should monitor your kidney function while taking this medicine.</li><li>experience any new visual changes. Your doctor should monitor your vision and eye health while taking this medicine.</li><li>are taking a medicine that is a moderate or strong CYP3A inducer. These types of medicines should be avoided (see Other medicines and Zokinvy, below).</li><li>are taking a medicine that is a moderate CYP3A inhibitor. Adding Zokinvy to an existing treatment with these types of medicines requires caution (see Other medicines and Zokinvy, below).</li><li>have a known dysfunctional polymorphism in CYP3A4. * have a progeroid syndrome caused by a mutation in a gene other than LMNA or ZMPSTE24 and do not cause a build-up of the harmful proteins called progerin or progerin-like proteins. Zokinvy is not expected to be effective for these types of progeroid syndromes. Examples of progeroid syndromes that Zokinvy is not expected to provide benefit include, Werner syndrome, Bloom syndrome, Rothmund Thomson syndrome, Cockayne syndrome, xeroderma pigmentosum, trichothiodystrophy and ataxia-telangiectasia.</li></ul><p>Children</p><p>Do not give this medicine to children under 12 months of age because it has not been studied in this age group.</p><p>Other medicines and Zokinvy</p><p>Tell your doctor or pharmacist if you are taking or might take any other medicines.</p><p>Some medicines may interact with Zokinvy when taken together. The following medicines must not be taken with Zokinvy:</p><ul><li>medicines that are strong CYP3A inhibitors (they can reduce the breakdown of Zokinvy in the body, leading to more side effects; ask your pharmacist or doctor if any of your other medicines are of this kind)</li><li>midazolam (used to treat seizures and for surgical procedures - tell your doctor you are taking Zokinvy if you are planning to have surgery)</li><li>atorvastatin, lovastatin or simvastatin (used to lower blood cholesterol)</li></ul><p>The following medicines require caution when taken with Zokinvy:</p><ul><li>medicines that are moderate CYP3A inhibitors (adding Zokinvy to an existing treatment with this kind of medicines requires caution; ask your pharmacist or doctor if any of your other medicines are of this kind). If you are already taking this kind of medicine your doctor may reduce your starting dose of Zokinvy.</li><li>medicines that are strong, moderate or weak CYP3A inducers (these can increase the breakdown of Zokinvy in the body, making the medicine less effective; ask your pharmacist or doctor if any of your other medicines are of this kind)</li><li>loperamide (used to treat diarrhoea). The dose of loperamide should not exceed 1 mg daily. Children less than 2 years of age should not take loperamide.</li><li>metformin (used to treat type 2 diabetes)</li><li>medicines that are CYP2C19 substrates (ask your pharmacist or doctor if any of your other medicines are of this kind). If you must take a CYP2C19 substrate, your doctor may need to adjust your dose of the CYP2C19 substrate and monitor your side effects more closely.</li><li>St. John s wort or St. John s wort-containing products (a herbal medicine used to treat mild depression)</li><li>medicines that are P-glycoprotein substrates (ask your pharmacist or doctor if any of your other medicines are this kind). If you must take a P-glycoprotein substrate, your doctor may need to adjust your dose of the P-glycoprotein substrate and monitor your side effects more closely.</li><li>medicines that are OCT1 substrates (ask your pharmacist or doctor if any of your other medicines are this kind)</li><li>oral contraceptives</li></ul><p>Zokinvy with food and drink</p><p>Do not take Zokinvy with foods or drinks that contain grapefruit, cranberries, pomegranates, or Seville (bitter) orange (such as orange marmalade). Foods or drinks containing these fruits may increase the side effects of Zokinvy.</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Zokinvy has not been tested in pregnant women.</p><p>Zokinvy is not recommended during pregnancy.</p><p>Females of childbearing potential must use effective contraception while taking Zokinvy and for at least 1 week after the final dose. Males with female partners of childbearing potential must use effective contraception while taking Zokinvy and for at least 3 months after the final dose. Add a barrier method of contraception if systemic steroids are used for contraception.</p><p>It is not known if Zokinvy passes into breast milk and could affect a breast-fed baby. If you wish to breast feed, discuss the benefits and possible risks of doing so or of stopping Zokinvy with your doctor first.</p><p>It is not yet known if this medicine affects fertility in men or women.</p><p>Driving and using tools or machines</p><p>Zokinvy has a minor influence on the ability to drive and use machines. Fatigue may occur following administration of Zokinvy.</p><p>Zokinvy contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take zokinvy",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take zokinvy"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><ul><li>Zokinvy is taken as 1 or 2 capsules twice a day, about 12 hours apart (morning and evening) with food. The dose of Zokinvy is based on your height and weight.</li><li>Your doctor will work out the right starting dose of Zokinvy for you. This may mean taking capsules of different strengths to make up the right amount. After 4 months of treatment with Zokinvy, your doctor may increase your dose.</li><li>Make sure you know how many capsules you need to take at every dose and the strength of each capsule you need. Ask your doctor, pharmacist or nurse to write it down (including the colour of the capsule(s) to be taken for each dose).</li><li>Take the capsules with food, washing them down with enough water to help you swallow them. Taking Zokinvy with food may help to reduce side effects.</li></ul><p>If you cannot swallow a Zokinvy capsule whole</p><ul><li>If you cannot swallow a Zokinvy capsule whole, use the following directions for mixing the capsule content with orange juice.</li></ul><p>What you need to mix Zokinvy with orange juice</p><ul><li>Mix a fresh dose of Zokinvy for each use.</li><li>Set aside the right number of Zokinvy capsules for your dose. Place the capsule or capsules on a clean flat surface.</li><li>Use orange juice only. Do not use other drinks to mix Zokinvy.</li><li>A clean medicine cup with 5 mL and 10 mL measurement levels.</li><li>A clean cup for each Zokinvy capsule to be mixed.</li><li>A clean spoon for stirring the mixture.</li></ul><p>How to mix Zokinvy with orange juice</p><p>Step 1:</p><ul><li><p>Using a clean medicine cup, measure either 5 mL or 10 mL of orange juice.</p></li><li><p>You can choose to use 5 mL or 10 mL of orange juice. Step 2:</p></li></ul><p>Pour the orange juice measured in Step 1 into a clean cup.</p><p>Step 3:</p><ul><li>Hold a Zokinvy capsule above the cup containing the orange juice.</li><li>Hold the capsule between your thumb and forefinger on both sides.</li><li>Gently twist and pull apart the capsule.</li></ul><p>Step 4: Empty all the contents of the capsule into the cup containing the orange juice.</p><p>Step 5:</p><ul><li>Using a clean spoon, mix the capsule contents and orange juice well.</li><li>If only 1 capsule is to be taken, skip to Step 7. * If 2 capsules are to be taken, proceed to Step 6. Step 6:</li><li>If 2 capsules will be taken, repeat Steps 1 through 5 for the second capsule.</li><li>Once the second capsule is mixed - the 2 servings can either be combined in a single cup or remain in 2 serving cups.</li><li>After you finish, go to Steps 7, 8 and 9. Step 7: Take all of the Zokinvy mixture:</li><li>with food.</li><li>within about 10 minutes of preparing.</li></ul><p>Each dose must be mixed and consumed within 10 minutes. The mixture should only be prepared at the time it is to be consumed.</p><p>Step 8: Rinse the medicine cup used to measure the orange juice and fill it with 5 mL of water for each capsule mixed with orange juice.</p><p>Step 9:</p><ul><li>Pour the water measured in Step 8 into the cup used to mix the Zokinvy and orange juice (a).</li><li>Gently swirl the water around the cup (b). Consume the water.</li></ul><p>If you need a reduced daily dose of Zokinvy</p><p>Step 1:</p><p>Use a clean medicine cup and fill it with 10 mL of orange juice.</p><p>Step 2:</p><p>Pour the orange juice measured in Step 1 into a clean cup for mixing.</p><p>Step 3:</p><ul><li>Depending on your doctor s direction, hold either a Zokinvy 75 mg or 50 mg capsule above the cup containing the orange juice.</li><li>Hold the capsule between your thumb and forefinger on both sides.</li><li>Gently twist and pull apart the capsule.</li></ul><p>Fill with 10 mL of orange juice (a) (b)</p><p>Step 4:</p><ul><li>Empty all the contents of the capsule into the cup containing the orange juice.</li></ul><p>Step 5:</p><p>Using a clean spoon, mix the capsule contents and orange juice well.</p><p>Step 6:</p><p>Pour 5 mL of the orange juice and Zokinvy mixture from the mixing cup into a clean medicine cup.</p><p>Step 7:</p><p>Take the 5-mL Zokinvy and orange juice mixture from the medicine cup:</p><ul><li>with food</li><li>within about 10 minutes of preparing</li></ul><p>Each dose must be mixed and consumed within 10 minutes. The mixture should only be prepared at the time it is to be consumed.</p><p>Step 8:</p><p>Fill the medicine cup used to consume the Zokinvy and orange juice mixture with 5 mL of water.</p><p>Fill to<br/>5 mL Fill to 5 mL</p><p>Step 9:</p><p>Gently swirl the water around the medicine cup. Consume the water.</p><p>Drink lots of water while taking Zokinvy</p><p>It is important to drink lots of water and other liquids while taking Zokinvy. This may help to reduce problems linked to diarrhoea or vomiting.</p><p>Ask your doctor about the amount of water or other liquids that you should drink each day.</p><p>Your doctor will discuss with you which liquids you can drink to make sure that you are getting the correct amount of fluids each day.</p><p>Do not eat foods or drink juices that contain grapefruit, cranberries, pomegranates or Seville oranges (known as sour or bitter oranges).</p><p>If you take more Zokinvy than you should</p><p>If you take more capsules than you should, stop taking the medicine and contact your doctor.</p><p>If you forget to take Zokinvy</p><p>If you forget to take a dose, and 8 hours or more remain until your next planned dose, take the missed dose as soon as possible with some food. If less than 8 hours remains before the next scheduled dose, skip the missed dose and resume taking Zokinvy at the next scheduled dose.</p><p>If you stop taking Zokinvy</p><p>Do not stop taking Zokinvy without talking to your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects. Tell your doctor immediately if you:</p><ul><li>have persistent nausea, vomiting or diarrhoea that leads to loss of appetite, weight loss or dehydration. Vomiting or diarrhoea are very common (may affect more than 1 in 10 people) and may lead to electrolyte deficiencies requiring supportive care. Your doctor may monitor your weight, appetite and how much you eat and drink to help detect any of these possible electrolyte conditions.</li></ul><p>Tell your doctor immediately if you notice any of the serious side effects above.</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li><p>increased liver enzymes shown by blood tests, which indicate stress on the liver</p></li><li><p>stomach pain</p></li><li><p>fatigue (tiredness)</p></li><li><p>constipation</p></li><li><p>sinus infections or other upper respiratory tract infections</p></li><li><p>decreased haemoglobin shown by blood tests</p></li><li><p>decreased bicarbonate shown by blood tests</p></li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>body aches and body pain, including back pain and pain in extremity</li><li>fever</li><li>decease in levels of sodium, potassium, albumin, creatinine shown by blood tests</li><li>increase in levels of magnesium shown by blood tests</li><li>cough</li><li>flatulence</li><li>rash</li><li>pruritus (itchy skin)</li><li>cerebral ischaemia (stroke)</li><li>headache</li><li>runny nose</li><li>nasal congestion (blocked nose)</li><li>nosebleed</li><li>sore throat</li><li>depression</li><li>oral pustule (mouth sores)</li><li>painful boil-like swelling near the anus (perirectal abscess)</li><li>pneumonia</li><li>influenza</li><li>decrease in blood cell counts (such as white blood cell count) shown by blood tests</li><li>tingling in hands and feet</li><li>dizziness</li><li>irritation, inflammation or ulcers of the large intestine (colitis)</li><li>indigestion (may include feelings of bloating, discomfort, feeling too full or gas)</li><li>inflammation of the stomach lining (gastritis)</li><li>bleeding of the large intestine, rectum or anus</li><li>dry skin</li><li>skin darkening (hyperpigmentation)</li><li>chest pain</li><li>chills</li><li>tooth fracture</li></ul><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store zokinvy",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store zokinvy"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP . The expiry date refers to the last day of that month.</p><p>Store in the original package. Keep the bottle tightly closed in order to protect from moisture. This medicinal product does not require any special temperature storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Zokinvy contains</p><ul><li><p>The active substance is lonafarnib Zokinvy 50 mg hard capsules: each capsule contains 50 mg lonafarnib. Zokinvy 75 mg hard capsules: each capsule contains 75 mg lonafarnib.</p></li><li><p>The other ingredients are: Capsule contents: croscarmellose sodium (see section 2 Zokinvy contains sodium ), magnesium stearate, poloxamer, povidone and silica, colloidal anhydrous Capsule shell: Zokinvy 50 mg hard capsules: gelatin, titanium dioxide, yellow iron oxide and sunflower lecithin Zokinvy 75 mg hard capsules: gelatin, titanium dioxide, yellow iron oxide, red iron oxide and sunflower lecithin Printing ink: shellac, iron oxide black</p></li></ul><p>What Zokinvy looks like and contents of the pack</p><p>Zokinvy 50 mg hard capsules are opaque yellow hard capsules, marked with LNF and 50 in black ink.</p><p>Zokinvy 75 mg hard capsules are opaque light orange hard capsules, marked with LNF and 75 in black ink.</p><p>The bottle pack contains 30 hard capsules and a desiccant. The desiccant is in a cannister and that cannister is included in the bottle, containing the capsules.</p><p>Marketing Authorisation Holder EigerBio Europe Ltd. 1 Castlewood Avenue Rathmines, D06 H685, Ireland</p><p>Manufacturer ABF Pharmaceutical Services GmbH Brunner Stra e 63/18-A-1230 Vienna Austria</p><p>Sciensus International B.V. Bijsterhuizen 36604 LV, Wijchen Netherlands</p><p>This leaflet was last revised in MONTH YEAR</p><p>This medicine has been authorised under exceptional circumstances . This means that because of the rarity of this disease it has been impossible to get complete information on this medicine. The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp899927b87eee0edddf78e53b80fec139",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp899927b87eee0edddf78e53b80fec139",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp899927b87eee0edddf78e53b80fec139\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp899927b87eee0edddf78e53b80fec139</b></p><a name=\"mp899927b87eee0edddf78e53b80fec139\"> </a><a name=\"hcmp899927b87eee0edddf78e53b80fec139\"> </a><a name=\"mp899927b87eee0edddf78e53b80fec139-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1660/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Zokinvy 50 mg hard capsules</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/22/1660/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Zokinvy 50 mg hard capsules",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
